BridgeBio initiated with an Outperform at RBC Capital

RBC Capital analyst Luca Issi initiated coverage of BridgeBio (BBIO) with an Outperform rating and $100 price target A survey of 40 cardiologists suggests the Attruby remains in the “early innings of the uptake,” the analyst tells investors in a research note. While ongoing tafamidis legal dispute has implications for the durability of the franchise, generic Vyndamax is unlikely to enter the market any time soon, the analyst tells investors in a research note. RBC also believes the rest of BridgeBio’s pipeline remains largely underappreciated at current share levels.